Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bcbe39c3059b1147e5c9b4c71dcff7f0c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bcbe39c3059b1147e5c9b4c71dcff7f0c NCIT_P378 "NCI" @default.
- Bcbe39c3059b1147e5c9b4c71dcff7f0c type Axiom @default.
- Bcbe39c3059b1147e5c9b4c71dcff7f0c annotatedProperty IAO_0000115 @default.
- Bcbe39c3059b1147e5c9b4c71dcff7f0c annotatedSource NCIT_C129448 @default.
- Bcbe39c3059b1147e5c9b4c71dcff7f0c annotatedTarget "A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 protein (PD-1, PCDC-1), with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation." @default.